Structured self-monitoring of blood glucose reduces glycated hemoglobin in insulin-treated diabetes

Noriko Kato*, Jinyan Cui, Mitsutoshi Kato

ABSTRACT
The aim of the present study was to investigate the effectiveness of structured self-monitoring of blood glucose (SMBG) in insufficiently controlled insulin-treated diabetes. A total of 86 insulin-treated patients were randomized to a routine testing group (RTG; n = 43) and a structured testing group (STG; n = 43). The STG used a chart to record seven-point blood glucose (BG) profile on three consecutive days per month. The primary end-point was the glycated hemoglobin (HbA1c) at 3 months and 6 months. There were no significant differences of HbA1c between the RTG and STG at 3 months. However, the STG had significantly improved HbA1c at 6-month follow-up compared with the RTG (P = 0.002). In the STG, HbA1c decreased by 0.5% from 7.9 (SD 0.5) to 7.4 (0.7)% whereas it decreased by 0.1% in the RTG from 7.9 (0.5) to 7.8 (0.7)% In the STG, 55% of the patients were willing to continue structured SMBG and they achieved a 0.7% decrease of HbA1c. The present findings suggest that structured SMBG significantly improves glycemic control. (J Diabetes Invest, doi: 10.1111/jdi.12072, 2013)

KEY WORDS: Glycemic control, Insulin-treated diabetes, Self-monitoring of blood glucose

INTRODUCTION
Self-monitoring of blood glucose (SMBG) is widely recommended as a component of diabetes management1,2. There is a general consensus that SMBG should be implemented by a more structured and standardized approach for patients with type 2 diabetes3. The International Diabetes Federation (IDF) provides several examples of focused SMBG regimens. One of which involves obtaining a seven-point blood glucose (BG) profile (before and 2-hour after each meal, and at bedtime) over three consecutive days (7-point 3-day testing)4. The recent Structured Testing Program Study showed that this structured seven-point 3-day testing regimen can significantly reduce glycated hemoglobin (HbA1c) when used by appropriately trained non-insulin-treated patients and their carers5. However, there has not been a study examining this SMBG regimen in insulin-treated patients. We considered that the seven-point 3-day structured SMBG regimen could achieve a better understanding of the BG profile by obtaining comprehensive BG data, and thus could lead to improved treatment.

The cost of SMBG is reimbursed for insulin-treated diabetes by the National Health Scheme in Japan. We investigated whether carrying out structured seven-point 3-day SMBG and charting the BG profile could improve glycemic control in insufficiently controlled insulin-treated patients without any additional cost.

MATERIALS AND METHODS
Participants
The present study was a randomized controlled trial that compared the structured testing group (STG) with the routine testing group (RTG). The study duration was 3 months, with an additional 3 months of follow up. Patients visited Kato Clinic of Internal Medicine (Kato Clinic), which specializes in treating diabetes, for review once a month.

Inclusion criteria were: (i) insulin-treated diabetes registered at Kato Clinic; (ii) familiarity with SMBG, and (iii) HbA1c >6.9%.

The study was approved by the ethics committee of Nishi Tokyo Clinical Diabetes Study Group (approval number: 100223) and was carried out in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.

During the first 3-month period, the STG carried out a seven-point 3-day structured SMBG before each visit to the clinic. The BG values were recorded with the Accu-Chek® 360° View Blood Glucose Analysis System (360° View; Roche Diabetes Care, Roche Diagnostics GmbH, Mannheim, Germany), an easy-to-use graphing tool for seven-point 3-day testing (Figure S1).

During the next 3-month period, a subgroup of the STG continued the seven-point 3-day testing and recorded data with...
360° View (STG1), whereas the other subgroup went back to routine testing and logbook recording (STG2).

As the control group, the RTG carried out routine SMBG and recorded data in a logbook throughout the 6-month period.

An introduction to the 360° View was provided for the STG. Patients visited the clinic monthly, and their therapy was adjusted based on the SMBG data.

SMBG strips were supplied within the reimbursable range.

End-Points and Statistics
The primary end-point was the change of HbA1c from baseline to 3-month and 6-month. HbA1c (%) was estimated as a National Glycohemoglobin Standardization Program (NGSP) value6.

All results are shown as mean (standard deviation). Data were compared by Mann–Whitney U-test and Tukey test. A P-value of <0.05 was considered to be statistically significant.

RESULTS
A total of 100 out of 800 diabetic patients registered at Kato Clinic were recruited, and 86 patients (4 type 1 and 82 type 2 diabetes) were enrolled. Three patients dropped out and 83 patients completed the study (42 in the STG; 41 in the RTG). Additional 3-month follow-up data were available for these 83 patients. The STG patients either continued seven-point 3-day testing and recording data with the 360° View method (STG1, n = 23) or went back to routine testing (STG2, n = 19). Figure 1 shows a consort diagram of the participants.

Their demographic and disease characteristics at baseline are listed in Table 1. There were no significant differences between the two groups. All patients were treated with insulin and 56% injected insulin three or more times a day.

Changes of HbA1c
As shown in Figure 2 and Table 2, the change of HbA1c at 6-month was significantly larger in the STG than the RTG (−0.5% vs −0.1%, P = 0.002). No significant difference in the reduction of HbA1c was seen at 3-month.

Adherence to Structured SMBG
After 3-month, patients in the STG chose to either continue seven-point 3-day testing using the 360° View recording paper tool (STG1) or to resume their previous routine testing (STG2), recording data in a logbook. A total of 23 patients continued structured testing (STG1; 55%) and 19 patients discontinued it (STG2; 45%).

The STG1 showed further improvement of HbA1c from 8.0 (0.6) to 7.5 (0.5)% and 7.3 (0.6)% at baseline, 3-month and 6-month, respectively. The change of HbA1c was significantly larger than in the RTG, being −0.7% vs −0.1% (P = 0.002).

Figure 1 | Consort diagram of the patients. A total of 86 insulin-treated patients were randomized to the structured testing group (STG) or routine testing group (RTG), with two and one drop-outs during the 3-month study, respectively. A total of 41 patients in the RTG and 42 in the STG completed the 3-month study and follow-up until 6 months. In the STG, 19 returned to routine self-monitoring of blood glucose (SMBG) and 23 continued structured testing with the Accu-Chek® 360° View Blood Glucose Analysis System during follow up until 6 months. QOL, quality of life; STG1, a subgroup of the STG that continued the seven-point 3-day testing and recorded data with the Accu-Chek® 360° View Blood Glucose Analysis System; STG2, a subgroup that went back to routine testing and logbook recording.
By 3-month, α-glucosidase inhibitors α-GI was added-on to significantly more patients in the STG vs patients in the RTG (7 vs 1). The STG tested both preprandial and postprandial BG, whereas many patients in the RTG mainly monitored fasting BG. We saw increased prescription of other oral agents in the STG, but the differences between the two groups were not as significant as α-GI. We made fine adjust-
Currently, there is no published guideline for SMBG in Japan. It is up to the healthcare providers to suggest the timing and frequency of testing, whereas patients choose how to carry it out and record the data. We believe that the reason that STG improved HbA1c was multidimensional. It is important for healthcare providers and patients to share SMBG data, and collaborate in the treatment of diabetes.

The structured testing SMBG method used in the present study is effective (HbA1c), and can be implemented (adherence) in insulin-treated patients.

A limitation of the present study was the small number of patients and they were from one clinic. We wish to have this structured testing carried out in other clinics with more patients in a future study.

ACKNOWLEDGEMENTS

Many thanks to Dr. Robin Wagner (an employee of Roche Diagnostics Corporation) for her valuable discussion and advice, and Mr. Masafumi Saito for his help in statistics. None of the authors have any conflict of interest to declare in association with the submission of this manuscript.

REFERENCES

1. American Diabetes Association. Executive summary: standards of medical care in diabetes-2010. Diabetes Care 2010; 33: S4–S10.
2. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 541–559.
3. Schnell O, Alawi H, Battelino T, et al. Addressing schemes of self-monitoring of blood glucose in type 2 diabetes: a European perspective and expert recommendation. Diabetes Technol Ther 2011; 13: 959–965.
4. International Diabetes Federation. Guideline on self-monitoring of blood glucose in non-insulin treated type 2 diabetes. 2009, http://www.idf.org/guidelines/self-monitoring
5. Polonsky WH, Fisher L, Schikman CH, et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the structured testing program study. Diabetes Care 2011; 34: 262–267.
6. Seino Y, Nanjo K, Tajima N, et al. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212–228.
7. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma increments to overall diurnal hyperglycaemia of type 2 diabetes: variations with increasing levels of HbA1c. Diabetes Care 2003; 26: 881–885.
8. Guideline for Management of PostMeal Glucose in Diabetes. 2011, www.idf.org/2011-guideline-management-postmeal-glucose-diabetes.

SUPPORTING INFORMATION

Additional Supporting Information may be found in the online version of this article:

Figure S1 | Blood glucose pattern recorded with Accu-Chek® 360° View Blood Glucose Analysis System sheet and continuous glucose monitoring.